Detalles de la búsqueda
1.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35263519
2.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308971
3.
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Int J Cancer
; 148(10): 2557-2570, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33348420
4.
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Br J Cancer
; 125(5): 679-686, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34158598
5.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat
; 187(1): 155-165, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33591468
6.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120223
7.
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Am J Hematol
; 96(4): 428-435, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33421178
8.
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Br J Clin Pharmacol
; 86(9): 1836-1848, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32207164
9.
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Cancer
; 125(4): 533-540, 2019 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30570744
10.
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Cancer
; 125(7): 1113-1123, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30690710
11.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717303
12.
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 168(1): 127-134, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29164421
13.
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Breast Cancer Res Treat
; 167(3): 659-669, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29058175
14.
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Oncologist
; 22(3): 264-271, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28209746
15.
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Int J Cancer
; 139(1): 177-86, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26891420
16.
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Lancet Oncol
; 16(3): 338-48, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25701170
17.
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
Invest New Drugs
; 33(1): 187-93, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25335932
18.
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.
Cancer Invest
; 33(10): 477-82, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26460795
19.
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
Haematologica
; 100(5): 670-6, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25710456
20.
Everolimus plus exemestane as first-line therapy in HRâº, HER2â» advanced breast cancer in BOLERO-2.
Breast Cancer Res Treat
; 143(3): 459-67, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24362951